tiprankstipranks
Irhythm Technologies (IRTC)
NASDAQ:IRTC
US Market
IRTC
Irhythm Technologies
RESEARCH TOOLSreports
Want to see IRTC full AI Analyst Report?

Irhythm Technologies (IRTC) Stock Forecast & Price Target

605 Followers
See the Price Targets and Ratings of:

IRTC Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Irhythm
Technologies
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IRTC Stock 12 Month Forecast

Average Price Target

$158.11
▲(44.79% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Irhythm Technologies in the last 3 months. The average price target is $158.11 with a high forecast of $196.00 and a low forecast of $18.00. The average price target represents a 44.79% change from the last price of $109.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","62":"$62","107":"$107","152":"$152","197":"$197"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":196,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$196.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":158.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$158.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,62,107,152,197],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.17,123.23384615384616,129.2976923076923,135.36153846153846,141.42538461538462,147.48923076923077,153.55307692307693,159.61692307692306,165.68076923076922,171.74461538461537,177.80846153846153,183.8723076923077,189.93615384615384,{"y":196,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.17,120.31931623931624,123.46863247863249,126.61794871794872,129.76726495726496,132.9165811965812,136.06589743589745,139.21521367521368,142.36452991452992,145.51384615384615,148.6631623931624,151.81247863247864,154.9617948717949,{"y":158.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,117.17,109.54153846153847,101.91307692307693,94.28461538461539,86.65615384615384,79.02769230769232,71.39923076923077,63.77076923076923,56.142307692307696,48.51384615384616,40.88538461538462,33.25692307692309,25.628461538461536,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":164.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.74,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.44,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.53,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.17,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$196.00Average Price Target$158.11Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on IRTC
Suraj Kalia
Oppenheimer
Oppenheimer
$185
Buy
69.41%
Upside
Assigned
08/10/26
Oppenheimer Reaffirms Their Buy Rating on Irhythm Technologies (IRTC)
Truist Financial Analyst forecast on IRTC
Richard Newitter
Truist Financial
Truist Financial
$160→$18
Buy
-83.52%
Downside
Reiterated
08/10/26
Truist Financial Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Evercore ISI Analyst forecast on IRTC
Vijay Kumar
Evercore ISI
Evercore ISI
$150→$165
Buy
51.10%
Upside
Reiterated
08/07/26
iRhythm price target raised to $165 from $150 at Evercore ISIiRhythm price target raised to $165 from $150 at Evercore ISI
Robert W. Baird Analyst forecast on IRTC
David Rescott
Robert W. Baird
Robert W. Baird
$160→$165
Buy
51.10%
Upside
Reiterated
08/07/26
iRhythm price target raised to $165 from $160 at BairdiRhythm price target raised to $165 from $160 at Baird
Canaccord Genuity Analyst forecast on IRTC
William Plovanic
Canaccord Genuity
Canaccord Genuity
$157→$196
Buy
79.49%
Upside
Reiterated
08/07/26
iRhythm price target raised to $196 from $157 at CanaccordiRhythm price target raised to $196 from $157 at Canaccord
Needham Analyst forecast on IRTC
David Saxon
Needham
Needham
$255→$192
Buy
75.82%
Upside
Reiterated
08/07/26
Needham Remains a Buy on Irhythm Technologies (IRTC)
Bank of America Securities Analyst forecast on IRTC
Stephanie Elghazi
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
William Blair Analyst forecast on IRTC
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
iRhythm: Strong Q2 Beat, Upgraded Outlook and VitalConnect Acquisition Underscore Buy Rating
BTIG Analyst forecast on IRTC
Marie Thibault
BTIG
BTIG
$185
Buy
69.41%
Upside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Irhythm Technologies (IRTC)
Stephens Analyst forecast on IRTC
Mason Carrico
Stephens
Stephens
$160
Buy
46.52%
Upside
Initiated
07/22/26
iRhythm initiated with an Overweight at StephensiRhythm initiated with an Overweight at Stephens
Citi Analyst forecast on IRTC
Joanne Wuensch
Citi
Citi
$157
Buy
43.77%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA) and Irhythm Technologies (NASDAQ: IRTC)
Wells Fargo Analyst forecast on IRTC
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$200→$180
Buy
64.84%
Upside
Reiterated
05/01/26
Irhythm Technologies (IRTC) Receives a Buy from Wells Fargo
J.P. Morgan Analyst forecast on IRTC
Allen Gong
J.P. Morgan
J.P. Morgan
$215→$175
Buy
60.26%
Upside
Reiterated
05/01/26
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (NASDAQ: IRTC), Alnylam Pharma (NASDAQ: ALNY) and Avantor (NYSE: AVTR)
Goldman Sachs Analyst forecast on IRTC
David Roman
Goldman Sachs
Goldman Sachs
$147
Hold
34.62%
Upside
Reiterated
04/30/26
Goldman Sachs Sticks to Their Hold Rating for Irhythm Technologies (IRTC)
UBS Analyst forecast on IRTC
Patrick Wood
UBS
UBS
$195→$205
Buy
87.73%
Upside
Reiterated
12/02/25
iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer Analyst forecast on IRTC
Suraj Kalia
Oppenheimer
Oppenheimer
$185
Buy
69.41%
Upside
Assigned
08/10/26
Oppenheimer Reaffirms Their Buy Rating on Irhythm Technologies (IRTC)
Truist Financial Analyst forecast on IRTC
Richard Newitter
Truist Financial
Truist Financial
$160→$18
Buy
-83.52%
Downside
Reiterated
08/10/26
Truist Financial Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Evercore ISI Analyst forecast on IRTC
Vijay Kumar
Evercore ISI
Evercore ISI
$150→$165
Buy
51.10%
Upside
Reiterated
08/07/26
iRhythm price target raised to $165 from $150 at Evercore ISIiRhythm price target raised to $165 from $150 at Evercore ISI
Robert W. Baird Analyst forecast on IRTC
David Rescott
Robert W. Baird
Robert W. Baird
$160→$165
Buy
51.10%
Upside
Reiterated
08/07/26
iRhythm price target raised to $165 from $160 at BairdiRhythm price target raised to $165 from $160 at Baird
Canaccord Genuity Analyst forecast on IRTC
William Plovanic
Canaccord Genuity
Canaccord Genuity
$157→$196
Buy
79.49%
Upside
Reiterated
08/07/26
iRhythm price target raised to $196 from $157 at CanaccordiRhythm price target raised to $196 from $157 at Canaccord
Needham Analyst forecast on IRTC
David Saxon
Needham
Needham
$255→$192
Buy
75.82%
Upside
Reiterated
08/07/26
Needham Remains a Buy on Irhythm Technologies (IRTC)
Bank of America Securities Analyst forecast on IRTC
Stephanie Elghazi
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Irhythm Technologies (NASDAQ: IRTC) and Editas Medicine (NASDAQ: EDIT)
William Blair Analyst forecast on IRTC
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
iRhythm: Strong Q2 Beat, Upgraded Outlook and VitalConnect Acquisition Underscore Buy Rating
BTIG Analyst forecast on IRTC
Marie Thibault
BTIG
BTIG
$185
Buy
69.41%
Upside
Reiterated
08/07/26
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Irhythm Technologies (IRTC)
Stephens Analyst forecast on IRTC
Mason Carrico
Stephens
Stephens
$160
Buy
46.52%
Upside
Initiated
07/22/26
iRhythm initiated with an Overweight at StephensiRhythm initiated with an Overweight at Stephens
Citi Analyst forecast on IRTC
Joanne Wuensch
Citi
Citi
$157
Buy
43.77%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA) and Irhythm Technologies (NASDAQ: IRTC)
Wells Fargo Analyst forecast on IRTC
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$200→$180
Buy
64.84%
Upside
Reiterated
05/01/26
Irhythm Technologies (IRTC) Receives a Buy from Wells Fargo
J.P. Morgan Analyst forecast on IRTC
Allen Gong
J.P. Morgan
J.P. Morgan
$215→$175
Buy
60.26%
Upside
Reiterated
05/01/26
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (NASDAQ: IRTC), Alnylam Pharma (NASDAQ: ALNY) and Avantor (NYSE: AVTR)
Goldman Sachs Analyst forecast on IRTC
David Roman
Goldman Sachs
Goldman Sachs
$147
Hold
34.62%
Upside
Reiterated
04/30/26
Goldman Sachs Sticks to Their Hold Rating for Irhythm Technologies (IRTC)
UBS Analyst forecast on IRTC
Patrick Wood
UBS
UBS
$195→$205
Buy
87.73%
Upside
Reiterated
12/02/25
iRhythm price target raised to $205 from $195 at Morgan StanleyiRhythm price target raised to $205 from $195 at Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Irhythm Technologies

3 Months
David RescottRobert W. Baird
Success Rate
16/28 ratings generated profit
57%
Average Return
+6.09%
Copying David Rescott's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +6.09% per trade.
1 Year
Richard NewitterTruist Financial
Success Rate
13/26 ratings generated profit
50%
Average Return
+19.30%
Copying Richard Newitter's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.30% per trade.
2 Years
Richard NewitterTruist Financial
Success Rate
20/26 ratings generated profit
77%
Average Return
+27.63%
Copying Richard Newitter's trades and holding each position for 2 Years would result in 76.92% of your transactions generating a profit, with an average return of +27.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IRTC Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
7
8
11
8
Buy
11
14
18
19
15
Hold
3
2
2
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
23
28
30
23
In the current month, IRTC has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRTC average Analyst price target in the past 3 months is 158.11.
Each month's total comprises the sum of three months' worth of ratings.

IRTC Financial Forecast

IRTC Earnings Forecast

Next quarter’s earnings estimate for IRTC is $0.03 with a range of -$0.16 to $0.27. The previous quarter’s EPS was -$0.01. IRTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 54.78% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.
Next quarter’s earnings estimate for IRTC is $0.03 with a range of -$0.16 to $0.27. The previous quarter’s EPS was -$0.01. IRTC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 54.78% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.

IRTC Sales Forecast

Next quarter’s sales forecast for IRTC is $222.40M with a range of $221.76M to $225.00M. The previous quarter’s sales results were $224.17M. IRTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 67.08% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.
Next quarter’s sales forecast for IRTC is $222.40M with a range of $221.76M to $225.00M. The previous quarter’s sales results were $224.17M. IRTC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 67.08% of the time in the same period. In the last calendar year IRTC has Performed in-line its overall industry.

IRTC Stock Forecast FAQ

What is IRTC’s average 12-month price target, according to analysts?
Based on analyst ratings, Irhythm Technologies’s 12-month average price target is 158.11.
    What is IRTC’s upside potential, based on the analysts’ average price target?
    Irhythm Technologies has 44.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IRTC a Buy, Sell or Hold?
          Irhythm Technologies has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Irhythm Technologies’s price target?
            The average price target for Irhythm Technologies is 158.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $196.00 ,the lowest forecast is $18.00. The average price target represents 44.79% Increase from the current price of $109.2.
              What do analysts say about Irhythm Technologies?
              Irhythm Technologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of IRTC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.